Search Results for: biotech

By Kuldip K. Ambastha The stock of Regeneron Pharmaceuticals, Inc. (REGN), a biotechnology company with a portfolio of medicines for individuals with serious diseases, increased in price by +18.8% per share on the trading day of Thursday, September 8, 2022. Eylea (aka: aflibercept), an anti-blindness eye medication, was the cause of this price run-up, because …

Continue reading “What Caught Our Attention in the Investment World? – Week of September 6-9, 2022”

By Kuldip K. Ambastha Longeveron Inc. (LGVN), a biotechnology company focused on clinical stage therapies, had its stock price rise by +105.4% per share on Thursday, March 31, 2022. On this trading day, a great piece of news led to a great return. Lomecel-B has shown positive results from its Phase 1 trial testing on …

Continue reading “What Caught Our Attention in the Investment World? – Week of March 28-April 1, 2022”

By Kuldip K. Ambastha BioNTech SE (BNTX) is aiming to become a leading biotechnology company with a main focus on individualized cancer medicine. The company has also been successful in offering an mRNA-based, two-shot coronavirus vaccine called BNT162b2 (aka: Comirnaty and Tozinameran), which has become increasingly important due to the rise of the highly contagious …

Continue reading “What Caught Our Attention in the Investment World? – Week of August 9-13, 2021”

By Kuldip K. Ambastha On Friday, July 16, 2021, the stock of Moderna, Inc. (MRNA) was up by +10.3% for the trading day. Moderna, a biotechnology company, has been highly successful in its efforts to develop a coronavirus (COVID-19) vaccine. Late on Thursday, July 15, 2021, S&P Dow Jones Indices announced that Moderna will become …

Continue reading “What Caught Our Attention in the Investment World? – Week of July 12-16, 2021”

By Kuldip K. Ambastha Biogen Inc. (BIIB), a biotech company, had a memorable Monday of this past trading week. On Monday, June 7, 2021, Biogen had a +38.3% gain for the day on its stock. Biogen’s Alzheimer’s disease treatment was approved by the U.S. Food and Drug Administration (FDA) as part of an accelerated approval …

Continue reading “What Caught Our Attention in the Investment World? – Week of June 7-11, 2021”

By Kuldip K. Ambastha and Anil K. Ambastha On Tuesday, February 25, 2020, the stock of Moderna, Inc. (MRNA) rose by 27.8% for the day. As the coronavirus (COVID-19) has spread around the world and led to a sell-off in the capital markets, Moderna, Inc. announced that its coronavirus vaccine candidate is scheduled to be …

Continue reading “What Caught Our Attention in the Investment World? – Week of February 24-28, 2020”

By Kuldip K. Ambastha and Anil K. Ambastha On Monday, December 9, 2019, big news emerged in the mergers & acquisitions field in terms of Merck & Co., Inc. (MRK) buying ArQule, Inc. (ARQL) and Sanofi SA (SNY) buying Synthorx Inc. (THOR). Both Merck and Sanofi bought the smaller companies to enhance their capabilities in …

Continue reading “What Caught Our Attention in the Investment World? – Week of December 9-13, 2019”

By Kuldip K. Ambastha and Anil K. Ambastha On Thursday, December 5, 2019, there was “a tale of two cities,” to quote Charles Dickens. In the biotech arena, SAGE (Sage Therapeutics, Inc.) and AUPH (Aurinia Pharmaceuticals Inc.) were big movers. Sage Therapeutics delivered -59.7% for the day, while Aurinia Pharmaceuticals returned 78.8%. SAGE-217 is a …

Continue reading “What Caught Our Attention in the Investment World? – Week of December 2-6, 2019”

By Kuldip K. Ambastha and Anil K. Ambastha On October 22, 2019, Biogen Inc. (BIIB) delivered a 26.1% return for the day. This was the stock’s largest one-day percentage return in 23 years. Its Alzheimer’s drug (aducanumab) had previously been written off as a failure, but now will be getting a second chance at approval …

Continue reading “What Caught Our Attention in the Investment World? – Week of October 21-25, 2019”